Moreover, neutralization of IL-13 by IL-13Rα2-Fc administration (30) or use of a bifunctional therapeutic targeting IL-4 and IL-13 (31) prevented oxazolone-induced colitis in mouse models. Here, IL4 is linked to colitis.